MINT NEOADJUVANT PUBLICATIONS & ABSTRACTS
Clinical evidence from MINT
Evidence / Neoadjuvant / MINT
Neoadjuvant Chemotherapy for T3 Tumors in the Era of Precision MedicineโBiology Is Still King
Publication: International Journal of Molecular Sciences 2025, 26, 491 Authors: Rakhshanda Layeequr Rahman, Alfredo Santillan, Mehran Habibi, Peter Beitsch, Pat Whitworth, Harshini Ramaswamy, Nicole Chmielewski-Stivers, Andrea Menicucci, William Audeh, and Joyce OโShaughnessy Title: Neoadjuvant Chemotherapy for T3 Tumors in the Era of Precision MedicineโBiology Is Still King Abtract: Clinical Read More
The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy
Publication: Annals of Surgical Oncology, Sept 1 2023 Authors: Peter Blumencranz MD, FACS, Mehran Habibi MD, Steve Shivers PhD, Geza Acs MD, Lisa E. Blumencranz PhD, Erin B. Yoder MS, Bastiaan van der Baan MS, Andrea R. Menicucci PhD, Patricia Dauer PhD, William Audeh MD & Charles E. Cox MD
Read MoreMammaPrint and BluePrint as prognostic indicators for elderly patients with early-stage breast cancer
PUBLICATION: SABCS 2020 AUTHORS: Peter W. Blumencranz, Mehran Habibi, Lisa Blumencranz, Andrea Menicucci, Shiyu Wang, Amy Truitt, William Audeh, Jolanta L. Baginski, Steven Shivers, Geza Acs, Charles E. Cox, MINT Investigators Group. Background: Elderly breast cancer (BC) patients are an understudied population, with limited evidence regarding treatment options and Read More